MedPath

Pfizer Corporation Hong Kong Limited

🇭🇰Hong Kong, China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

217

PPB:217

Drug Approvals

TALZENNA CAPSULES 0.1MG

Approval Date
Nov 18, 2024
PPB

LITFULO CAPSULES 50MG

Approval Date
Jun 28, 2024
PPB

ELREXFIO SOLUTION FOR INJECTION 44MG/1.1ML

Approval Date
May 6, 2024
PPB

ELREXFIO SOLUTION FOR INJECTION 76MG/1.9ML

Approval Date
May 6, 2024
PPB

ABRYSVO VACCINE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Approval Date
Apr 29, 2024
PPB

XELJANZ ORAL SOLUTION 1MG/ML

Approval Date
Apr 8, 2024
PPB

NGENLA SOLUTION FOR INJECTION IN PRE-FILLED PEN 24MG/1.2ML

Approval Date
Sep 15, 2023
PPB

NGENLA SOLUTION FOR INJECTION IN PRE-FILLED PEN 60MG/1.2ML

Approval Date
Sep 15, 2023
PPB

RAPAMUNE ORAL SOLUTION 1MG/ML

Approval Date
Aug 8, 2023
PPB

PREVENAR 20 VACCINE

Approval Date
Apr 28, 2023
PPB
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 22
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.